Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

A. T. Paquete; M. Gouveia; R. Guerreiro; J. Anjo; C. Magalhaes; M. Borges

Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

A. T. Paquete^*, M. Gouveia, R. Guerreiro, J. Anjo, C. Magalhaes, M. Borges

^*Autor correspondente para este trabalho

Resultado de pesquisa › revisão de pares

Idioma original	English
Número do artigo	PCN67
Páginas (de-até)	S448-S448
Número de páginas	1
Revista	Value in Health
Volume	22
Número de emissão	S3
Estado da publicação	Publicado - nov. 2019
Evento	ISPOR Europe 2019 - Bella Center Copenhagen, Copenhagen Duração: 2 jan. 2019 → 6 nov. 2019

Citação

@article{92adbf2cf78e49b2b5bf6b2b43143de7,

title = "Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal",

author = "Paquete, {A. T.} and M. Gouveia and R. Guerreiro and J. Anjo and C. Magalhaes and M. Borges",

year = "2019",

month = nov,

language = "English",

volume = "22",

pages = "S448--S448",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier Ltd.",

number = "S3",

note = "ISPOR Europe 2019 ; Conference date: 02-01-2019 Through 06-11-2019",

}

Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal. / Paquete, A. T.; Gouveia, M.; Guerreiro, R. et al.
Em: Value in Health, Vol. 22, N.º S3, PCN67, 11.2019, p. S448-S448.

Resultado de pesquisa › revisão de pares

TY - JOUR

T1 - Cost-effectiveness analysis of daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy in Portugal

AU - Paquete, A. T.

AU - Gouveia, M.

AU - Guerreiro, R.

AU - Anjo, J.

AU - Magalhaes, C.

AU - Borges, M.

PY - 2019/11

Y1 - 2019/11

M3 - Meeting Abstract

SN - 1098-3015

VL - 22

SP - S448-S448

JO - Value in Health

JF - Value in Health

IS - S3

M1 - PCN67

T2 - ISPOR Europe 2019

Y2 - 2 January 2019 through 6 November 2019

ER -